In recent years, the success of CAR-T therapies in treating patients with hematological malignancies by targeting CD19 or BCMA has revolutionized cancer treatment, and many CAR-T cells have been developed for use against other leukemic antigens or solid tumors [1,2,36]; however, relapses occur after CAR-T cell therapies, and several clinical studies have shown that the injection of CAR-T cells with a less differentiated phenotype, such as TSCM and TCM, are particularly attractive because of their ability to induce long-lasting anti-tumor immunity [8,28,29,30,37]. Here, CD19 is linked to hematologic disorder.